Brain cancer vaccine trial aims to stop tumor return
NCT ID NCT07520214
First seen Apr 18, 2026 · Last updated May 08, 2026 · Updated 1 time
Summary
This early-stage study tests two mRNA vaccines (GV-108 and GV-907) in 9 adults with a specific type of aggressive brain cancer (IDH-wildtype glioblastoma). The goal is to see if the vaccines are safe and can trigger the immune system to fight the cancer, potentially preventing recurrence after standard treatment. Participants must have had complete tumor removal and no signs of recurrence at the start.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA IDH (ISOCITRATE DEHYDROGENASE) WILDTYPE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Tiantan Hospital
Beijing, Beijing Municipality, 100050, China
Conditions
Explore the condition pages connected to this study.